Paul Edick Joins Sucampo’s Board of Directors
July 29 2016 - 6:30AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced that Paul Edick will
join Sucampo's Board of Directors on August 1. Mr. Edick is
the former CEO of Durata Therapeutics and currently the founding
partner of 3G Advisors.
"I am pleased to welcome Paul to Sucampo’s Board
of Directors," said Peter Greenleaf, Chairman and Chief Executive
Officer of Sucampo. “Paul is a well-rounded and seasoned
chief executive with a depth of experience in building and leading
specialty pharmaceutical companies. With the addition of
Paul, we have assembled a world-class Board of Directors with the
experience to help Sucampo execute on our growth strategy focused
on diversification of our portfolio of commercial and
development-stage products."
Mr. Edick brings over 35 years of experience in
the life sciences industry to Sucampo. He has extensive commercial
and senior operational experience, most recently serving as chief
executive officer and a board member of Durata Therapeutics, Inc.
from July 2010 to November 2014. From 2008 to 2010, Mr. Edick
was chief executive officer of Ganic Pharmaceuticals, Inc., a
Warburg Pincus investment search vehicle, and prior to that he was
chief executive officer at MedPointe Healthcare, Inc. He has
also held a number of senior positions at GD Searle & Company,
and at Pharmacia Corporation following its acquisition of the
company, culminating in his appointment as Pharmacia’s Group Vice
President and President for Asia and Latin America.
Mr. Edick received his B.A. in psychology from
Hamilton College. Mr. Edick currently serves as a director
for PDL BioPharma, Inc.; NewLink Genetics, Inc. and Neos
Therapeutics, Inc. He also serves as Chairman of the Board of
Iterum Therapeutics, a private company.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is focused on the
development and commercialization of medicines that meet major
unmet medical needs of patients worldwide. Sucampo has two marketed
products – AMITIZA, its lead product, and RESCULA – and a pipeline
of product candidates in clinical development. A global company,
Sucampo is headquartered in Rockville, Maryland, and has operations
in Japan, Switzerland and the U.K. For more information, please
visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo
Pharmaceuticals).Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024